Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Free Cash Flow (2020 - 2022)

Atea Pharmaceuticals (AVIR) has 3 years of Free Cash Flow data on record, last reported at -$21.5 million in Q4 2022.

  • For Q4 2022, Free Cash Flow rose 71.43% year-over-year to -$21.5 million; the TTM value through Dec 2022 reached -$122.9 million, down 41.28%, while the annual FY2025 figure was -$132.0 million, 2.56% up from the prior year.
  • Free Cash Flow reached -$21.5 million in Q4 2022 per AVIR's latest filing, down from -$21.3 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $318.5 million in Q4 2020 and bottomed at -$75.4 million in Q4 2021.
  • Average Free Cash Flow over 3 years is $7.2 million, with a median of -$17.1 million recorded in 2021.
  • The widest YoY moves for Free Cash Flow: up 338.03% in 2021, down 273.49% in 2021.
  • A 3-year view of Free Cash Flow shows it stood at $318.5 million in 2020, then plummeted by 123.68% to -$75.4 million in 2021, then soared by 71.43% to -$21.5 million in 2022.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were -$21.5 million in Q4 2022, -$21.3 million in Q3 2022, and -$20.4 million in Q2 2022.